Prostate cancer biomarker study using tumor DNA in blood to predict treatment outcomes
Official title: Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes
Funded at Fred Hutchinson Cancer Center · NIH-11398968 · Data updated 2026-11-12
A study to see if DNA from a patient’s blood can predict how well prostate cancer treatments will work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $602,496 |
| NIH project number | 5R01CA280056-04 |
| Project ID | NIH-11398968 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with prostate cancer who may be candidates for ARSI or PSMA-targeted therapies and who have or are at risk of treatment resistance.
✕Less likely to help
Patients whose cancer does not shed detectable tumor DNA into the bloodstream or whose treatment plan is not influenced by the identified biomarkers.
What this research studies
This project will collect blood samples from men with prostate cancer and analyze circulating tumor DNA to identify biomarkers that reflect the cancer’s phenotype and genotype. By comparing blood-based DNA patterns with treatment responses, the researchers aim to find noninvasive indicators that predict who will benefit from AR-targeted therapies and PSMA-directed treatments. The study will address tumor heterogeneity and resistance mechanisms while aiming to reduce the need for invasive biopsies. If successful, the approach could guide personalized treatment decisions and monitoring in real time.
Why it matters
Potential benefit: If successful, patients could receive more personalized, timely treatment plans based on a simple blood test.
How similar studies have gone: Previous work shows circulating tumor DNA can reflect tumor characteristics, but linking it to specific treatment outcomes in CRPC is still being explored.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Ha, Gavin — Fred Hutchinson Cancer Center
- Study coordinator: Ha, Gavin
Related research
Other NIH-funded projects on the same topics.
-
Predicting prostate cancer treatment response using tumor DNA from blood
This project seeks to find out if analyzing tumor DNA in blood can show which men with advanced prostate cancer will respond to androgen-targeted and PSMA-directed therapies.
-
Using blood tests to identify prostate cancer characteristics for better treatment predictions
This study is looking at how bits of cancer DNA found in your blood can help doctors understand your prostate cancer better and predict how well different treatments might work for you, especially when regular biopsies are tough to do.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.